Abstract:The p53 tumor suppressor gene plays a key role in prevention of tumor formation through transcriptional dependent and independent mechanisms. Transcriptional-dependent mechanisms are mainly mediated by p53 regulation of downstream targets, leading to growth arrest and apoptosis. Mutational inactivation of the p53 gene is detected in more than 50% of human cancers. Mutation of p53 renders cancer cells more resistant to current cancer therapies due to lack of p53-mediated apoptosis. Extensive studies have been conducted to identify small molecules that manipulate p53, including restoration of mutant p53 conformation to wild-type, disruption of murine double minute-2 (Mdm2)-p53 binding to increase p53 level and inhibition of Mdm2 E3 ubiquitin ligase activity to prevent p53 degradation. Another approach was to identify and validate "drugable" target(s) in p53 signaling pathways that modulate p53-induced apoptosis. We profiled a p53 temperature-sensitive lung cancer cell model with the Affymetrix human HG-U133 GeneChip, covering the entire human transcriptome. We identified thousands of unique genes that were either induced or repressed in response to p53-induced apoptosis. A follow-up study characterized a p53-repressed gene, SAK, a polo-like kinase (PLK) family member, as an appealing cancer drug target. Snk/Plk-akin kinase (SAK) silencing via small interfering RNA (siRNA) induced apoptosis, whereas SAK overexpression attenuated p53-induced apoptosis. Thus, SAK repression by p53 contributes to p53-induced apoptosis. Future work is directed at determining the normal cell response to SAK silencing. If a therapeutic window is obtained, a SAK inhibitor identified from high throughput screening (HTS) could serve as a lead compound for development of a novel class of apoptosis-inducing anticancer drugs.

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Small Molecule Inhibitors of the P53-Mdm2

Current strategies to target p53 in cancer.

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Targeting P53 for Novel Anticancer Therapy.

Activating p53 with a Mutant-Specific Small Molecule

P53 and Its Downstream Proteins As Molecular Targets of Cancer

Pharmacological Activation of the P53 Pathway Within the Tumor Microenvironment Induces Immunogenic Cell Death of Tumors and Enhances Antitumor Immunity

The Development of P53-Targeted Therapies for Human Cancers

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Restoration of p53 to limit tumor growth

Mechanism-specific signatures for small-molecule p53 activators

Therapeutic targeting of p53 by small molecules

Modeling the Etiology of p53-mutated Cancer Cells

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Reactivation of P53 by a Specific MDM2 Antagonist (MI-43) Leads to P21-Mediated Cell Cycle Arrest and Selective Cell Death in Colon Cancer.

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis